resveratrol has been researched along with cardiovascular agents in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 12 (50.00) | 24.3611 |
| 2020's | 4 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, LN; Tang, YH; Zang, WJ | 1 |
| Hao, HD; He, LR | 1 |
| Cui, W; Han, C; Jia, X; Li, N; Liu, C; Liu, Z; Mao, W; Song, Y; Wang, W; Zhang, W; Zhang, X | 1 |
| Liu, ZP; Liu, ZQ; Song, Y; Zhang, XP | 1 |
| Chen, J; Fan, F; Han, L; Wang, S; Wang, X; Xie, X; Yan, J; Zhou, X | 1 |
| Chandrasekar, B; Cortez, DM; Mummidi, S; Prabhu, SD; Valente, AJ; Venkatachalam, K | 1 |
| Cantos-Villar, E; García-Parrilla, MC; Guerrero, RF; Puertas, B | 1 |
| Arora, R; Sadruddin, S | 1 |
| Asmis, R; Ullevig, SL; Zamora, D; Zhao, Q | 1 |
| Förstermann, U; Li, H; Xia, N | 1 |
| Bendeck, MP; Breen, DM; Dandona, P; Dolinsky, VW; Dyck, JR; Ghanim, H; Giacca, A; Guo, J; Heximer, SP; Mroziewicz, M; Tsiani, EL; Zhang, H | 1 |
| Lu, XQ; Ruan, BF; Song, J; Zhu, HL | 1 |
| Espín, JC; García-Conesa, MT; González-Sarrías, A; Larrosa, M; Tomás-Barberán, FA; Tomé-Carneiro, J | 1 |
| Czernizer, E; Dardik, A; Dardik, H; Hoffmann, T; London, D; Naftalovich, R; Orozco-Sevilla, V; Yang, C | 1 |
| Dugas, TR; Khandelwal, AR; Kleinedler, JJ; McInnis, MC; Orr, AW; Spence, AL; Yurdagul, A | 1 |
| Albertini, M; Calvillo, L; Casana, R; Cilurzo, F; Mazzola, S; Selmin, F; Tolva, V; Zerbi, P | 1 |
| Dyck, JR; Robertson, IM; Zordoky, BN | 1 |
| Deng, S; Li, C; Ma, X; Nawaz, W; Shu, X; Zhou, Z | 1 |
| Chen, T; Huang, W; Liang, G; Qian, J; Sun, C; Wang, J; Xu, Z; Ye, S; You, S; Zhang, H | 1 |
| Ai, J; Asadpour, S; Ghanbari, H; Khademi, F; Yeganeh, H | 1 |
| Gal, R; Habon, T; Halmosi, R; Kenyeres, P; Praksch, D; Rabai, M; Toth, K | 1 |
| Carvalho, GC; Chorilli, M; Ferrari, PC; Riccio, BVF; Spósito, L | 1 |
| Alós, J; Arjumand, J; Härtel, D; Hohl, C; Korosoglou, G; Langhoff, R; Martínez, E; Raut, W; Reimer, P; Riazi, H; Romani, S; Schmidt, A; Waliszewski, M; Yahya, SA | 1 |
| Asghari, A; Jamialahmadi, T; Parsamanesh, N; Sahebkar, A; Sardari, S; Tasbandi, A; Xu, S | 1 |
11 review(s) available for resveratrol and cardiovascular agents
| Article | Year |
|---|---|
[Progress in cardiovascular protective effects of resveratrol].
Topics: Animals; Antioxidants; Arteriosclerosis; Cardiovascular Agents; Humans; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Resveratrol; Stilbenes; Vasodilator Agents | 2003 |
Mechanisms of cardiovascular protection by resveratrol.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Antioxidants; Cardiovascular Agents; Cardiovascular Diseases; Cell Division; Humans; Phytoestrogens; Resveratrol; Signal Transduction; Stilbenes | 2004 |
Wine, resveratrol and health: a review.
Topics: Anticoagulants; Antineoplastic Agents, Phytogenic; Biological Availability; Cardiovascular Agents; Diet, Mediterranean; Humans; Lipid Metabolism; Neoplasms; Protective Agents; Resveratrol; Stilbenes; Vitis; Wine | 2009 |
Resveratrol: biologic and therapeutic implications.
Topics: Animals; Blood Glucose; Caloric Restriction; Cardiovascular Agents; Cardiovascular Diseases; Dietary Carbohydrates; Dietary Fats; Energy Intake; Homeostasis; Humans; Lipid Metabolism; Metabolic Syndrome; Molecular Structure; Resveratrol; Sirtuin 1; Sirtuins; Stilbenes | 2009 |
Cardiovascular effects and molecular targets of resveratrol.
Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Humans; Molecular Targeted Therapy; Nitric Oxide; Resveratrol; Stilbenes | 2012 |
Derivatives of resveratrol: potential agents in prevention and treatment of cardiovascular disease.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cardiovascular Agents; Cardiovascular Diseases; Humans; Hydroxamic Acids; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Resveratrol; Sirtuin 1; Stilbenes | 2012 |
Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.
Topics: Animals; Anticarcinogenic Agents; Cardiovascular Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Evidence-Based Medicine; Humans; Randomized Controlled Trials as Topic; Resveratrol; Stilbenes; Tissue Distribution; Treatment Outcome | 2013 |
Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases.
Topics: Animals; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Heart Rate; Humans; Resveratrol; Stilbenes; Vasodilation | 2015 |
Therapeutic Versatility of Resveratrol Derivatives.
Topics: Antineoplastic Agents; Antioxidants; Cardiovascular Agents; Humans; Molecular Structure; Neuroprotective Agents; Resveratrol; Stilbenes | 2017 |
Resveratrol isoforms and conjugates: A review from biosynthesis in plants to elimination from the human body.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Biotransformation; Cardiovascular Agents; Drug Elimination Routes; Food; Gastrointestinal Absorption; Humans; Hypoglycemic Agents; Isomerism; Plants; Resveratrol | 2020 |
Resveratrol and endothelial function: A literature review.
Topics: Angiogenesis Inhibitors; Animals; Antihypertensive Agents; Cardiovascular Agents; Cardiovascular Diseases; Endothelial Cells; Endothelium, Vascular; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Resveratrol; Signal Transduction | 2021 |
1 trial(s) available for resveratrol and cardiovascular agents
| Article | Year |
|---|---|
Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol.
Topics: Aged; Cardiovascular Agents; Double-Blind Method; Erythrocyte Aggregation; Exercise Tolerance; Female; Heart Failure; Humans; Hungary; Male; Middle Aged; Resveratrol; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2020 |
12 other study(ies) available for resveratrol and cardiovascular agents
| Article | Year |
|---|---|
Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model.
Topics: Angiotensin II; Animals; Blood Pressure; Cardiomegaly; Cardiovascular Agents; Endothelin-1; Hypertension, Renal; Male; Myocardium; Nephrectomy; Nitric Oxide; Rats; Rats, Sprague-Dawley; Resveratrol; Stilbenes | 2005 |
[Preventive effect of trans-resveratrol on hypertension-induced cardiac hypertrophy in partially nephrectomized rats].
Topics: Angiotensin II; Animals; Cardiomegaly; Cardiovascular Agents; Endothelin-1; Hypertension; Male; Myocardium; Nephrectomy; Nitric Oxide; Random Allocation; Rats; Rats, Sprague-Dawley; Resveratrol; Stilbenes | 2005 |
Resveratrol inhibits proliferation of cultured rat cardiac fibroblasts: correlated with NO-cGMP signaling pathway.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Cardiovascular Agents; Cell Proliferation; Cell Size; Cells, Cultured; Cyclic GMP; Fibroblasts; Intracellular Space; L-Lactate Dehydrogenase; Male; Natriuretic Peptide, Brain; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Oxadiazoles; Quinoxalines; Rats; Rats, Sprague-Dawley; Resveratrol; Signal Transduction; Stilbenes | 2007 |
Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts.
Topics: Animals; Cardiovascular Agents; Cell Culture Techniques; Cells, Cultured; Collagen; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Flavonoids; Glucose; Hyperglycemia; Interleukin-17; Male; Mice; Mice, Inbred C57BL; Myocardium; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptors, Interleukin; Receptors, Interleukin-17; Resveratrol; RNA, Messenger; Signal Transduction; Stilbenes; Time Factors; Up-Regulation | 2008 |
Ursolic acid protects diabetic mice against monocyte dysfunction and accelerated atherosclerosis.
Topics: Animals; Aortic Diseases; Atherosclerosis; Cardiovascular Agents; Cell Line; Chemokine CCL2; Chemotaxis, Leukocyte; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Humans; Hyperlipidemias; Kidney; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Oxidative Stress; Receptors, CCR2; Receptors, LDL; Resveratrol; Stilbenes; Time Factors; Triterpenes; Ursolic Acid | 2011 |
Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism.
Topics: Administration, Oral; Animals; Aorta; Cardiovascular Agents; Carotid Arteries; Carotid Artery Injuries; Cell Proliferation; Disease Models, Animal; Enzyme Inhibitors; Femoral Artery; Gene Expression Regulation; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; Neointima; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Sprague-Dawley; Resveratrol; RNA, Messenger; Stilbenes; Time Factors; Vascular System Injuries | 2012 |
Epigallocatechin-3-gallate is a potent phytochemical inhibitor of intimal hyperplasia in the wire-injured carotid artery.
Topics: Animals; Cardiovascular Agents; Carotid Artery Injuries; Carotid Artery, Common; Carotid Intima-Media Thickness; Catechin; Cell Proliferation; Disease Models, Animal; Disulfides; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Hyperplasia; Injections, Intraperitoneal; Isothiocyanates; Male; Neointima; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Resveratrol; Stilbenes; Sulfinic Acids; Sulfoxides; Time Factors | 2013 |
Resveratrol promotes endothelial cell wound healing under laminar shear stress through an estrogen receptor-α-dependent pathway.
Topics: Animals; Cardiovascular Agents; Carotid Arteries; Cell Proliferation; Endothelium, Vascular; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Female; In Vitro Techniques; Mice; Mice, Inbred Strains; Models, Animal; Nitric Oxide Synthase Type III; Paclitaxel; Regional Blood Flow; Resveratrol; Shear Strength; Signal Transduction; Stilbenes; Stress, Mechanical; Wound Healing | 2014 |
A successful experimental model for intimal hyperplasia prevention using a resveratrol-delivering balloon.
Topics: Angioplasty, Balloon; Animals; Cardiovascular Agents; Cell Proliferation; Cells, Cultured; Coated Materials, Biocompatible; Disease Models, Animal; Equipment Design; Humans; Hyperplasia; Iliac Artery; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neointima; Rabbits; Resveratrol; Stilbenes; Vascular Access Devices; Vascular System Injuries | 2016 |
An Aza resveratrol-chalcone derivative 6b protects mice against diabetic cardiomyopathy by alleviating inflammation and oxidative stress.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Apoptosis; Cardiovascular Agents; Cell Line; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Gene Expression Regulation; Glucose; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Rats; Resveratrol; Signal Transduction; Streptozocin | 2018 |
Resveratrol-loaded polyurethane nanofibrous scaffold: viability of endothelial and smooth muscle cells.
Topics: Biocompatible Materials; Blood Vessel Prosthesis; Cardiovascular Agents; Cell Proliferation; Cell Survival; Drug Delivery Systems; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Materials Testing; Microscopy, Electron, Scanning; Myocytes, Smooth Muscle; Nanofibers; Nanotechnology; Polyurethanes; Resveratrol; Tissue Scaffolds | 2019 |
The Real-World CONSEQUENT ALL COMERS Study: Predictors for Target Lesion Revascularization and Mortality in an Unselected Patient Population.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Cause of Death; Coated Materials, Biocompatible; Europe; Female; Femoral Artery; Humans; Malaysia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Resveratrol; Risk Assessment; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2021 |